928844-26-2

Basic information

• Product Name: 1H-Indole-6-carboxamide, 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-
• CAS NO: 928844-26-2
• Molecular Formula: C25H29N3O5S
• Molecular Weight: 483.588
• Mol File: 928844-26-2.mol

Chemical Properties

• CAS DataBase Reference: 1H-Indole-6-carboxamide, 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-6-carboxamide, 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-(928844-26-2)
• EPA Substance Registry System: 1H-Indole-6-carboxamide, 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-(928844-26-2)

Safety Data

• Hazardous Substances Data: 928844-26-2(Hazardous Substances Data)

Usage

Chemical structure

1H-Indole-6-carboxamide, 3-cyclohexyl-N-[(dimethylamino)sulfonyl]-2-(2-formyl-4-methoxyphenyl)-

Indole core

The compound has an indole core, which is a bicyclic aromatic system consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

Carboxamide group

A carboxamide group (-CONH2) is attached to the indole core at position 6.

Cyclohexyl group

A cyclohexyl group (a six-carbon ring with a hydrocarbon chain) is attached to the nitrogen atom of the indole core.

Dimethylamino and sulfonyl groups

The compound contains a dimethylamino (-N(CH3)2) group and a sulfonyl (-SO2) group, both connected to the nitrogen atom.

Formyl-methoxyphenyl group

A 2-(2-formyl-4-methoxyphenyl) group is attached to the indole ring, which consists of a benzene ring with a formyl (-CHO) group at position 2 and a methoxy (-OCH3) group at position 4.

Potential applications

The compound may have potential applications in pharmaceuticals, agrochemicals, or materials science.

Further research needed

Additional research and testing are required to determine the specific uses and properties of this complex compound.

Upstream product

• 108-94-1 cyclohexanone 
• 902148-40-7 2-bromo-3-cyclohexyl-N-[(dimethylamino)sulfonyl]-1H-indole-6-carboxamide 
• 50820-65-0 indole-6-carboxylic acid methyl ester 
• 494799-16-5 3-(cyclohex-1-en-1-yl)-1H-indole-6-carboxylic acid 
• 494799-17-6 3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 494799-76-7 2-bromo-3-cyclohexyl-1H-indole-6-carboxylic acid 
• 139962-95-1 2-formyl-4-methoxyphenylboronic acid 
• 64-17-5 ethanol 
• 958002-14-7 6H-Isoindolo[2,1-a]indole-3-carboxamide, 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-ethoxy-8-methoxy- 

Downstream Products

• 958002-14-7 6H-Isoindolo[2,1-a]indole-3-carboxamide, 11-cyclohexyl-N-[(dimethylamino)sulfonyl]-6-ethoxy-8-methoxy- 
• 902148-54-3 13-cyclohexyl-10-[[[(dimethylamino)sulfonyl]amino]carbonyl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-6-carboxylic acid methyl ester 
• 945686-46-4 (1aR,12bS)-8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid methyl ester 
• 928843-71-4 (1aR,12bS)-8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid 
• 1532561-34-4 (1aR,12bS)-8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((2R)-2-(methoxymethyl)morpholin-4-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]-benzazepine-5-carboxamide 
• 959983-22-3 cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, (+/-)- 
• 959983-21-2 cycloprop[d]indolo[2,1-a][2]benzazepine-1a(2H)-carboxylic acid, 8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxy-, methyl ester, (+/-)- 
• 959983-11-0 1,1-dimethylethyl (8-cyclohexyl-5-((((dimethylamino)sulfonyl)amino)carbonyl)-11-(methyloxy)-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl)carbamate 
• 959983-12-1 1a-amino-8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-(methyloxy)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide hydrochloride 
• 902148-42-9 13-cyclohexyl-10-[[((dimethylamino)sulfonyl)amino]carbonyl]-3-methoxy-7H-indolo[2,1a][2]benzazepine-6-carboxylic acid 
• 959983-23-4 8-cyclohexyl-5-(((dimethylamino)sulfonyl)carbamoyl)-11-methoxy-1,12b-dihydrocyclopropa[d]indolo[2,1-a][2]benzazepine-1a(2H)-carbonyl azide 
• 1045705-30-3 8-cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-((4-morpholinylsulfonyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 
• 1045705-05-2 8-cyclohexyl-N-((dimethylamino)sulfonyl)-11-(methyloxy)-1a-((4-morpholinyl(oxo)acetyl)amino)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide 

Relevant articles and documents

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase

Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors. Subsequent iterations of analogue design and synthe

Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the Treatment of Hepatitis C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.